HLSE:BONEH

Stock Analysis Report

BBS-Bioactive Bone Substitutes Oyj

Executive Summary

BBS-Bioactive Bone Substitutes Oyj develops, designs, manufactures, and sells bioactive bone-graft substitute implants in Finland.

Snowflake

Fundamentals

Imperfect balance sheet with poor track record.

Risks

  • BBS-Bioactive Bone Substitutes Oyj is not covered by any analysts.

Share Price & News

How has BBS-Bioactive Bone Substitutes Oyj's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

12.8%

HLSE:BONEH

12.8%

FI Biotechs

0.3%

FI Market


1 Year Return

-23.1%

HLSE:BONEH

-23.1%

FI Biotechs

-4.1%

FI Market

BONEH underperformed the Biotechs industry which returned 7.8% over the past year.

BONEH underperformed the Market in Finland which returned -6.2% over the past year.


Share holder returns

BONEHIndustryMarket
7 Day12.8%12.8%0.3%
30 Day7.9%7.9%0.4%
90 Day-0.6%-0.6%-4.2%
1 Year-23.1%-23.1%-23.1%-23.1%-0.2%-4.1%
3 Yearn/a0%0%35.9%20.9%
5 Yearn/a0%0%54.6%25.9%

Price Volatility Vs. Market

How volatile is BBS-Bioactive Bone Substitutes Oyj's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BBS-Bioactive Bone Substitutes Oyj undervalued based on future cash flows and its price relative to the stock market?

39.48x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for BBS-Bioactive Bone Substitutes Oyj to establish if it is available at moderate discount.

Unable to calculate intrinsic value for BBS-Bioactive Bone Substitutes Oyj to establish if it is available at substantial discount.


Price Based on Earnings

BBS-Bioactive Bone Substitutes Oyj is overvalued based on earnings compared to the Europe Biotechs industry average.

BBS-Bioactive Bone Substitutes Oyj is overvalued based on earnings compared to the Finland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BBS-Bioactive Bone Substitutes Oyj, we can't assess if its growth is good value.


Price Based on Value of Assets

BBS-Bioactive Bone Substitutes Oyj is overvalued based on assets compared to the Europe Biotechs industry average.


Next Steps

Future Growth

How is BBS-Bioactive Bone Substitutes Oyj expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.8%

Forecasted Biotechs industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BBS-Bioactive Bone Substitutes Oyj has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BBS-Bioactive Bone Substitutes Oyj performed over the past 5 years?

-22.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BBS-Bioactive Bone Substitutes Oyj's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.

BBS-Bioactive Bone Substitutes Oyj has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

BBS-Bioactive Bone Substitutes Oyj has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.


Return on Equity

BBS-Bioactive Bone Substitutes Oyj has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

BBS-Bioactive Bone Substitutes Oyj used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

BBS-Bioactive Bone Substitutes Oyj has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is BBS-Bioactive Bone Substitutes Oyj's financial position?


Financial Position Analysis

BBS-Bioactive Bone Substitutes Oyj is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BBS-Bioactive Bone Substitutes Oyj's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

BBS-Bioactive Bone Substitutes Oyj's level of debt (143.3%) compared to net worth is high (greater than 40%).

Unable to establish if BBS-Bioactive Bone Substitutes Oyj's debt level has increased without past 5-year debt data.

Operating cash flow is negative therefore debt is not well covered.

Interest payments on debt are well covered by earnings (EBIT is 4.9x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.3x debt.


Next Steps

Dividend

What is BBS-Bioactive Bone Substitutes Oyj's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BBS-Bioactive Bone Substitutes Oyj's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BBS-Bioactive Bone Substitutes Oyj's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BBS-Bioactive Bone Substitutes Oyj has not reported any payouts.

Unable to verify if BBS-Bioactive Bone Substitutes Oyj's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BBS-Bioactive Bone Substitutes Oyj has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BBS-Bioactive Bone Substitutes Oyj's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average board tenure


CEO

Pekka Jalovaara (78yo)

16.4yrs

Tenure

Prof. Pekka Jalovaara, MD, PhD has been Chief Executive Officer of BBS-Bioactive Bone Substitutes Oyj since 2003 and serves as its President. Prof. Jalovaara founded BBS. He is a Professor of Orthopedics a ...


Board Age and Tenure

2.3yrs

Average Tenure

65yo

Average Age

The average tenure for the BBS-Bioactive Bone Substitutes Oyj board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Hannu Säynäjäkangas (65yo)

    CFO & Director

  • Paul Watkins

    Chief Commercial Officer & Member of Advisory Board

    • Tenure: 0.1yrs
  • Pekka Jalovaara (78yo)

    CEO, President & Director

    • Tenure: 16.4yrs
  • Hanna Tölli (36yo)

    Production Manager & HR Manager


Board Members

  • Jarmo Halonen (67yo)

    Chairman of the Board

  • Hannu Säynäjäkangas (65yo)

    CFO & Director

    • Tenure: 7.4yrs
  • Pekka Jalovaara (78yo)

    CEO, President & Director

    • Tenure: 16.4yrs
  • Kirk Andriano

    Member of Advisory Board

  • Ilkka Kangasniemi (55yo)

    Director

    • Tenure: 0.2yrs
  • Declan Flaherty

    Member of Advisory Board

  • Paul Watkins

    Chief Commercial Officer & Member of Advisory Board

  • Tomi Numminen

    Director

    • Tenure: 1.3yrs
  • Brent Atkinsson

    Member of Advisory Board

  • Auvo Kaikkonen (59yo)

    Director

    • Tenure: 2.3yrs

Company Information

BBS-Bioactive Bone Substitutes Oyj's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BBS-Bioactive Bone Substitutes Oyj
  • Ticker: BONEH
  • Exchange: HLSE
  • Founded: 2003
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: €15.272m
  • Shares outstanding: 5.09m
  • Website: Click here

Number of Employees


Location

  • BBS-Bioactive Bone Substitutes Oyj
  • Kiviharjunlenkki 6
  • Oulu
  • Northern Ostrobothnia
  • 90220
  • Finland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BONESOM (OMX Nordic Exchange Stockholm)YesRegistered SharesSESEKFeb 2018
BONEHHLSE (OMX Nordic Exchange Helsinki)YesRegistered SharesFIEURFeb 2018

Biography

BBS-Bioactive Bone Substitutes Oyj develops, designs, manufactures, and sells bioactive bone-graft substitute implants in Finland. It offers ARTEBON, an orthobiological product based on tricalcium phosphat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/18 22:37
End of Day Share Price2019/06/17 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.